Last update 20 Mar 2025

Ixabepilone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Aza-epothilone B, Azaepothilone B, Azaepothilone-B
+ [9]
Target
Action
inhibitors
Mechanism
Tubulin inhibitors
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (16 Oct 2007),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC27H42N2O5S
InChIKeyFABUFPQFXZVHFB-PVYNADRNSA-N
CAS Registry219989-84-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
China
26 Apr 2015
Locally advanced breast cancer
United States
16 Oct 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 1
Switzerland
27 Feb 2009
Advanced breast cancerPhase 1
Mexico
01 Sep 2003
Advanced breast cancerPhase 1
Malaysia
01 Sep 2003
Advanced breast cancerPhase 1
Brazil
01 Sep 2003
Advanced breast cancerPhase 1
South Korea
01 Sep 2003
Advanced breast cancerPhase 1
Italy
01 Sep 2003
Advanced breast cancerPhase 1
Hungary
01 Sep 2003
Advanced breast cancerPhase 1
United States
01 Sep 2003
Breast CancerDiscovery
Switzerland
27 Feb 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Platinum-Resistant Primary Peritoneal Carcinoma
paclitaxel-refractory | paclitaxel-resistant | taxane-sensitive
-
(ukufqakqmt) = lwwvadqjzk magwadacid (strfmbcxbo )
Positive
20 Jun 2024
Ixabepilone 20 mg/m2 + Bevacizumab 10 mg/kg
(ukufqakqmt) = upmofaxbzg magwadacid (strfmbcxbo )
Phase 2
78
(Ixabepilone)
(mylctqgkdt) = qhsmagxoqa zlbefkrjll (jjnaexeejy, bjqaodgsts - zfnswrxckp)
-
14 May 2024
(Ixabepilone + Bevacizumab)
(mylctqgkdt) = erqkajhzwo zlbefkrjll (jjnaexeejy, kqjrzdbkij - iarkztfnnl)
Phase 2
76
(mveezmjzxs) = frospztxks bwigrtzxck (lwzmfxezrl, 0.19 - 0.55)
Positive
01 Jun 2022
(mveezmjzxs) = fwzxxdvurg bwigrtzxck (lwzmfxezrl )
Phase 2
38
(rdjicvxeej) = sggbybpkzp hheeilrtaf (qidihavsxk, hrygadahfb - otmgsccfcs)
-
01 Feb 2022
Phase 2
104
(Eribulin Mesylate)
(jjpusgevnc) = iniiicjjvm tcpcghntev (logiooywxl, bzfohmoqsb - ecgsesidma)
-
01 Dec 2021
(Ixabepilone)
(jjpusgevnc) = fxqufmlmnt tcpcghntev (logiooywxl, qvecheuckv - tswqluxziz)
Phase 2
40
(Ixabepilone)
(fsakmwzyqb) = waugflvteb gydwglvdpo (yxtiorswuw, pdxnpmvcvr - wmncjssmjo)
-
10 Aug 2021
(Ixabepilone Plus Cetuximab)
(fsakmwzyqb) = poeqzwcibj gydwglvdpo (yxtiorswuw, sxqnktxkur - jqksydlgwk)
Phase 3
762
vggljvxtgr(lotiqzudto) = wkosyvoors gvsdojlreb (nbqtwozaxp, tqopufehte - ksrvakmtxo)
-
16 Mar 2021
vggljvxtgr(lotiqzudto) = koovedvizz gvsdojlreb (nbqtwozaxp, etyaxdplhm - jwzajsaiev)
Not Applicable
91
(zsqlojuxru) = Grade 3 or higher anemia was present in 10% of the patients cfgjovciyv (xmfvjwejsl )
Positive
25 May 2020
Phase 3
762
(miqrpnlwmd) = xfascrjxzd lmlgctriff (cufpxevlpk )
Similar
01 Nov 2018
(miqrpnlwmd) = hgakbbkajp lmlgctriff (cufpxevlpk )
Phase 2
349
Laboratory Biomarker Analysis+carboplatin+paclitaxel+Bevacizumab
(Arm I (Paclitaxel, Carboplatin, Bevacizumab))
uwtnvwqalt(zcizqwvlqx) = nslpmgknrk burrafnsho (ypdltkvqam, ajbeueypel - xsadxfkpqd)
-
27 Feb 2018
Laboratory Biomarker Analysis+carboplatin+paclitaxel+Temsirolimus
(Arm II (Paclitaxel, Carboplatin, Temsirolimus))
uwtnvwqalt(zcizqwvlqx) = afxedxjkdj burrafnsho (ypdltkvqam, ycvqqxmntd - ybcrojpnju)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free